Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Yung-Chi Cheng, William H. Prusoff · Biochemical Pharmacology · 1973 · 12.8K citations

Cent Inhibition, Inhibitory Activity, Biochemistry +8

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Mette Zander, Sten Madsbad, Jan Lysgaard Madsen et al. · The Lancet · 2002 · 1.3K citations

Metabolic Syndrome, Diabetes Management, Glucagon-like Peptide 1 +9

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

Rolf Mentlein, Baptist Gallwitz, Wolfgang E. Schmidt · European Journal of Biochemistry · 1993 · 1.2K citations · Full text

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Timothy J. Kieffer, Christopher H.S. McIntosh, Raymond A. Pederson · Endocrinology · 1995 · 1.1K citations

Glycobiology, Peptide Science, Peptide Chemistry +21

(2<i>R</i>)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-<i>a</i>]pyrazin- 7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 808 citations · Full text